exelixis

exelixis

NASDAQ:EXEL
Exelixis

Chart

Detailed Quote

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Featured Articles and Interviews
Top 5 Life Science ETFs

Top 5 Life Science ETFs

Needle injecting into red and white cell.

How to Invest in Biotechnology

Press Releases

Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Patients with Metastatic Colorectal Cancer

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June

The Conversation (0)